|Ho: Ibalizumab for HIV Prevention
|Prophylactic neutralizing Ab
|Study Start Date:
|Study Made Public:
In Vivo Activity of Ibalizumab Administered by Subcutaneous Injection
CAVD 310 is a non-human primate study comparing administration of the monoclonal antibody, Ibalizumab, via intravenous and subcutaneous routes.
Sign in to see full information about this study and to download study data.
NAb, NAb MAb
No non-integrated data is available for this study.